Search - tctmd.com

Displaying 401 - 420 of 564

Sort: Relevancy | Date

Presentation TCT 2015

TCT 73: Impact of Routine MicroNet-Covered Embolic Prevention Stent System Use on Contemporary Carotid Revascularization All-Comer PARADIGM Study

Presenter: Mark C. Bates, Mark H. Wholey, Piotr Musialek

October 13, 2015

Presentation TCT 2015

TCT 57: A Cost Analysis of Bleed Complications From 2 Stroke Prevention Strategies in Nonvalvular Atrial Fibrillation: Left Atrial Appendage Closure Versus Warfarin

Presenter: Jacqueline Saw, Steven J. Yakubov, Matthew J. Price

October 13, 2015

Presentation TCT 2015

Adjuvant Pharmacotherapy With Ranolazine In Patients With Ischemic Heart Disease

Presenter: Bernard J. Gersh, Stephen D. Wiviott, Giora Weisz

October 13, 2015

Presentation TCT 2015

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

Presenter: Bernard J. Gersh, Stephen D. Wiviott

October 13, 2015

Presentation TCT 2015

PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events

Presenter: Bernard J. Gersh, Stephen D. Wiviott, Evan A. Stein

October 13, 2015

Presentation TCT 2015

Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic?

Presenter: Bernard J. Gersh, Stephen D. Wiviott, David J. Maron

October 13, 2015

Presentation TCT 2015

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Presenter: Gary M. Ansel, Michael R. Jaff, Ori Ben-Yehuda

October 11, 2015

Presentation ESC 2015

Long-term Dual Antiplatelet Therapy for 2° Prevention of Cardiovascular Events in Patients with Previous Myocardial Infarction

Presenter: Jacob A. Udell

August 31, 2015

Presentation

Meta-analysis: LAA Closure as an Alternative to Warfarin for Stroke Prevention in A-fib

Presenter: David R. Holmes Jr

June 16, 2015

Presentation TVT 2015

Annulus Rupture During TAVR: Prevention and Management

Presenter: Marco Barbanti

June 05, 2015

Presentation TVT 2015

Coronary Obstruction During TAVR: Prevention and Management

Presenter: Howard C. Herrmann

June 05, 2015

Presentation TVT 2015

Prevention and Management of Conduction Disturbances and Arrhythmias (AF) After TAVR

Presenter: Tamim Nazif

June 05, 2015

Presentation TVT 2015

Coronary Obstruction During Aortic Valve-in-Valve Therapy: Predictors and Prevention

Presenter: Vinayak Bapat, Danny Dvir, Raj Makkar

June 05, 2015

Presentation

Association of Discharge Aspirin Dose With Outcomes After Acute MI

Presenter: Ying Xian

May 27, 2015

Presentation

Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After DES Implantation

Presenter: K.A. Fiedler

April 22, 2015

Presentation

Longitudinal Persistence With Secondary Prevention Therapies Relative to Patient Risk After MI

Presenter: Supriya Shore

April 02, 2015

Presentation ACC 2015

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Presenter: Marc S. Sabatine

March 14, 2015

Presentation

ITALIC: 6- vs 24-Month DAPT After Implantation of DES in Patients Nonresistant to Aspirin

Presenter: Martine Gilard

March 10, 2015

Presentation CADECI 2015

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

Presenter: DR. JOSE LUIS LEIVA PONS

February 20, 2015

Presentation

LAA Occlusion for Stroke Prevention in A-Fib

Presenter: Apostolos Tzikas

January 29, 2015

Advertisement

TCT 73: Impact of Routine MicroNet-Covered Embolic Prevention Stent System Use on Contemporary Carotid Revascularization All-Comer PARADIGM Study

TCT 57: A Cost Analysis of Bleed Complications From 2 Stroke Prevention Strategies in Nonvalvular Atrial Fibrillation: Left Atrial Appendage Closure Versus Warfarin

Adjuvant Pharmacotherapy With Ranolazine In Patients With Ischemic Heart Disease

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events

Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic?

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Long-term Dual Antiplatelet Therapy for 2° Prevention of Cardiovascular Events in Patients with Previous Myocardial Infarction

Meta-analysis: LAA Closure as an Alternative to Warfarin for Stroke Prevention in A-fib

Annulus Rupture During TAVR: Prevention and Management

Coronary Obstruction During TAVR: Prevention and Management

Prevention and Management of Conduction Disturbances and Arrhythmias (AF) After TAVR

Coronary Obstruction During Aortic Valve-in-Valve Therapy: Predictors and Prevention

Association of Discharge Aspirin Dose With Outcomes After Acute MI

Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After DES Implantation

Longitudinal Persistence With Secondary Prevention Therapies Relative to Patient Risk After MI

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

ITALIC: 6- vs 24-Month DAPT After Implantation of DES in Patients Nonresistant to Aspirin

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

LAA Occlusion for Stroke Prevention in A-Fib

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content